Skip to main content
. 2022 Sep 7;15:292. doi: 10.1186/s13104-022-06180-3

Fig. 2.

Fig. 2

aCL concentration in individuals vaccinated with ChAdOx1-S (A) and with BNT162b2 (B) across three sampling points, no earlier than a week before the second dose (T1), ≈ 21 days after the second dose (T2) and 3 months after (T3). A significant difference (p = 0.00391) was found in the concentration over time for the ChAdOx1-S (Fig. 2A). While no significant difference (p = 0.0874) was in the BNT162b2 vaccinated group over time